Parkinson's disease results from progressive loss of dopamine-producing neurons in the substantia nigra. Stem-cell research pursues two complementary routes: neurogenic cells differentiated toward dopamine neurons are studied to replace lost cells and restore dopamine signalling, while placental mesenchymal stem cells are explored for neuroprotection — slowing degeneration through anti-inflammatory and growth-factor secretion. Preclinical evidence suggests dopamine-releasing cells can reinnervate the striatum and that trophic factors may delay neuronal death. Key challenges are achieving cell survival, integration and functional restoration in a degenerating brain. Most trials are early-phase, with modest motor changes reported.
Sixty-nine registered trials and 16 recruiting studies investigate stem-cell approaches in Parkinson's. Small series document modest motor-symptom changes within 6–12 months, but are typically unblinded, single-arm, and lack sham controls. A few report dopamine-replacement activity on PET imaging; durability beyond 12 months is sparse. Heterogeneous cell products and delivery routes complicate interpretation. No trial has prevented progression or restored motor function to pre-disease levels.
Indicative European costs are roughly €4,000–€7,000 per infusion. If intracerebral delivery is used, stereotactic neurosurgery, imaging and intensive monitoring can double or triple the total. Some protocols use multiple infusions over months. For context, medical management runs €200–€1,000 monthly and deep-brain stimulation is a large one-time cost — the stem-cell figure is indicative and unproven.
Cell therapy for Parkinson's Disease is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Parkinson's Disease programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
← Back to Parkinson's Disease overview · Parkinson's Disease cost →
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita